Vergelijking
CagriSema vs. Efinopegdutide
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Metabool
Metabool
CAS-nr.
geen gegevens
2055640-93-0
Molecuulmassa
geen gegevens
geen gegevens
Halfwaardetijd
geen gegevens
115 h
Sequentie
geen gegevens
modifiziertes, von Oxyntomodulin abgeleitetes Peptid, konjugiert an ein humanes IgG4-Fragment (Verlängerung der Plasma-Halbwertszeit)Werkingsmechanisme
CagriSema
CagriSema combines two satiety pathways in one weekly injection: the amylin analogue cagrilintide and the GLP-1 agonist semaglutide. Both suppress appetite and food intake — together more than either component alone.
Efinopegdutide
Efinopegdutide is an oxyntomodulin-derived peptide acting as a dual agonist at the GLP-1 and glucagon receptors with a relative potency of approximately 2:1 (GLP-1 to glucagon). The GLP-1 component mediates glucose-dependent insulin secretion and modulation of satiety; the glucagon component increases energy expenditure and hepatic fat oxidation, which is proposed to contribute to the observed reduction in liver fat. Conjugation to an IgG4 fragment prolongs the half-life and enables weekly administration.
Bewijsbasis
Hoogste bewijs
Humane RCT
Humane RCT
Studies
1
3
waarvan bij mensen
1
3
Geregistreerde effecten
2
4
Openstaande tegenstrijdigheden
0
1
Gedocumenteerde bijwerkingen
1
1
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between CagriSema and Efinopegdutide?
- CagriSema is classified as "Metabool", while Efinopegdutide is classified as "Metabool". CagriSema: CagriSema is a fixed-dose combination of the amylin analogue cagrilintide and the GLP-1 agonist semaglutide (Novo Nordisk), in late-stage development for obesity and type 2 diabetes. Efinopegdutide: Efinopegdutide (MK-6024, formerly JNJ-64565111 / HM12525A) is a once-weekly dual agonist at the GLP-1 and glucagon receptors, developed by Hanmi and Merck. It has been studied for obesity and notably for metabolic liver disease (MASH/NAFLD); a phase-2 trial showed greater liver-fat reduction than semaglutide. Investigational, not approved. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, CagriSema or Efinopegdutide?
- The highest available evidence level is "Humane RCT" for CagriSema and "Humane RCT" for Efinopegdutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of CagriSema and Efinopegdutide in Germany and the United States?
- Duitsland: CagriSema — Niet goedgekeurd, Efinopegdutide — Niet goedgekeurd. Verenigde Staten: CagriSema — Niet goedgekeurd, Efinopegdutide — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.